Elementos para interoperabilidade de um software de seguimento farmacoterapêutico de pacientes com tuberculose

• Ano de defesa: 2011
• Autor(a) principal: Sessa, Elizoneth Campos Delorto
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal do Espírito Santo; BR; Mestrado em Doenças Infecciosas; Centro de Ciências da Saúde; UFES; Programa de Pós-Graduação em Doenças Infecciosas
• Palavras-chave em Português: Tuberculosis; Pharmacotherapeutic; Follow-up. Software; Interoperability; Tuberculose; Seguimento farmacoterapêutico; Software; Interoperabilidade; Doenças Infecciosas e Parasitárias; 61
• Link de acesso: http://repositorio.ufes.br/handle/10/5953

Introduction: Tuberculosis (TB) treatment is a combination of medications for at least six months. Normally patients are treated by several multidisciplinary teams serving different levels of care, including patient´s pharmaceutical care through pharmacotherapy follow-up. With the increase of technology, it is essential to adopt exchanging standards of information in order to have interoperability between systems/services. Objectives: This study aims to specify data and respective standards requirements for pharmacotherapeutic follow-up data management software with focus on TB treatment. Methods: Pharmacotherapeutic follow-up forms propose an implementation of the first computer system prototype; forms test and adjustment through following the pharmacotherapy of a set of 30 TB patients; review, discussion and define respective healthcare data exchange standards required for such data in order to implement software interoperability; implementation of these concepts in a second software prototype that produces XML documents in adherence to HL7-CDA (Health Level 7 - Clinical Document Architecture). Results: a set of forms for TB patients pharmacotherapeutic follow-up, delivering the essential content of a discharge/ follow-up summary. Such content, fully represented by heathcare informations exchange standards has been translated to HL7- CDA documents generated by the prototype software. Conclusion: The prototype was able to generate "discharge/ pharmacotherapeutic follow-up" summaries in adherence to HL7-CDA architecture. Thus, it will allow systems interoperability throughout control and monitoring of TB pharmacotherapy patients.